Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 1
1968 3
1969 3
1970 5
1971 3
1972 2
1973 5
1974 3
1975 8
1976 6
1977 8
1978 8
1979 15
1980 12
1981 14
1982 18
1983 19
1984 11
1985 9
1986 22
1987 22
1988 30
1989 24
1990 25
1991 26
1992 45
1993 49
1994 54
1995 72
1996 100
1997 118
1998 94
1999 121
2000 116
2001 106
2002 98
2003 135
2004 150
2005 167
2006 191
2007 197
2008 244
2009 268
2010 242
2011 233
2012 273
2013 242
2014 293
2015 286
2016 255
2017 244
2018 197
2019 167
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

4,577 results
Results by year
Filters applied: . Clear all
Page 1
Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, Bruheim P, Mjøs SA, Angelsen A, Bathen TF, Tessem MB. Giskeødegård GF, et al. Br J Cancer. 2015 Dec 22;113(12):1712-9. doi: 10.1038/bjc.2015.411. Epub 2015 Dec 3. Br J Cancer. 2015. PMID: 26633561 Free PMC article.
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R. Scher HI, et al. JAMA Oncol. 2016 Nov 1;2(11):1441-1449. doi: 10.1001/jamaoncol.2016.1828. JAMA Oncol. 2016. PMID: 27262168 Free PMC article.
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW. Vandekerkhove G, et al. Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10. Eur Urol. 2019. PMID: 30638634
Cell surface blood group antigens in prostatic carcinoma.
Walker PD, Karnik S, deKernion JB, Pramberg JC. Walker PD, et al. Am J Clin Pathol. 1984 Apr;81(4):503-6. doi: 10.1093/ajcp/81.4.503. Am J Clin Pathol. 1984. PMID: 6702753
Multiparametric liquid biopsy analysis in metastatic prostate cancer.
Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, Dempsey PW, Pagano PC, Bischoff F, Khurana A, Koo S, Ting M, Cotter PD, Moore MW, Gunn S, Usher J, Rabizadeh S, Danenberg P, Danenberg K, Carpten J, Dorff T, Quinn D, Goldkorn A. Hodara E, et al. JCI Insight. 2019 Mar 7;4(5):e125529. doi: 10.1172/jci.insight.125529. eCollection 2019 Mar 7. JCI Insight. 2019. PMID: 30702443 Free PMC article.
Blood group distribution in prostatic cancer patients.
Wajsman Z, Saroff J, Murphy GP. Wajsman Z, et al. J Surg Oncol. 1977;9(3):289-91. doi: 10.1002/jso.2930090311. J Surg Oncol. 1977. PMID: 875395
Plasma FGF23 is not elevated in prostate cancer.
Vlot MC, Bijnsdorp I, den Heijer M, de Jonge R, van Moorselaar RJA, Heijboer AC. Vlot MC, et al. Clin Chim Acta. 2018 Mar;478:129-131. doi: 10.1016/j.cca.2017.12.035. Epub 2017 Dec 23. Clin Chim Acta. 2018. PMID: 29277536 No abstract available.
Current Management Strategy for Active Surveillance in Prostate Cancer.
Syed JS, Javier-Desloges J, Tatzel S, Bhagat A, Nguyen KA, Hwang K, Kim S, Sprenkle PC. Syed JS, et al. Curr Oncol Rep. 2017 Feb;19(2):11. doi: 10.1007/s11912-017-0569-6. Curr Oncol Rep. 2017. PMID: 28220449 Review.
4,577 results
Jump to page
Feedback